Abstract:SUMMARY Many potential drug candidates pose potent anti-tumor activities, but they have either low solubility or high toxicities. We identified a novel Wnt pathway inhibitor, which displays anti-tumor activities through inhibition of tumor cell proliferations. However, it has low solubility and high toxicity. In our current study, we prepared RH40 micelles to encapsulate the drug, in order to improve its solubility and reduce its toxicity in animals. The micelle formulation could be administered intravenously and improve the drug distribution in tumor tissue/cells. Potentially, this strategy may allow us to overcome the hurdle of low solubility of drugs in order to improve their anti-tumor efficacy and reduce non-target toxicity. INTRODUCTION We have identified a novel compound CL010, which is an inhibitor targeting at the Wnt pathway. It was discovered through screening efforts using cell models for inhibiting signaling Wnt pathway. Our in vitro study indicated that it is highly potent in inhibiting growth and proliferation of cancer cells overexpressing of RSPO2/3. A few in vivo primary tumor models were established in order to test in vivo anti-tumor activities of CL010. However, CL010 was found to have very poor water solubility, which would restrict investigation of its dose responses in vivo. Therefore, improving the aqueous solubility of CL010 is essential before we can initiate in vivo studies to test its efficacy in animal models via different dosing schemes. In addition, the compound CL010 appeared to be toxic to mice when administered in vivo. Thus, the current study aims to improve the compound solubility and reduce its toxicity through micelle technology. EXPERIMENTAL METHODS 1. Preparation of micelle formulations containing the compound CL010: CL010 were dissolved in tert-butyl alcohol and mixed with water containing 20% cremophor RH40 and 5% mannitol. The solvents were removed by lyophilization. The lyophilized powder was then rehydrated with water. The anti-wnt compounds in micelles could increase its concentration to 3 mg/ml. This is a big improvement over its maximum solubility in water. (Table 1. Size distribution of the micelle) 2. Animal model setup: We select two gastric and one liver primary tumor samples, cut human tumor samples into 1 mm × 1 mm × 1 mm fragments, implant in 6-8 weeks old nude mice, start treatment when tumors reach 200 mm (length × width × width) / 2, dose mice via IV, and PO, and measure tumor size and bodyweight twice a week. RESULTS AND DISCUSSION We used the micelle formulation to prepare the CL010 compounds to dose animal via IV (Figure 1). The results show that there is difference in tumor sizes in the group treated with micelle-formulated CL010 compound, while the bodyweight of the treated mice were not reduced. Therefore, above studies demonstrated that micelle formulation improved the solubility of the compound CL010, and reduced its toxic effects on mice. Table1. Size distribution of the micelle with CL010 Figure1. In vivo testing of CL010 packed in micelle formulation on the Gastric #1 model. CONCLUSION Using an anti-Wnt pathway inhibitor, we have demonstrated that micelle formulations containing compound CL010 had improved its solubility. In addition, the micelle formation appears to reduce its toxic effects in vivo when given via IV. Therefore, we conclude that micelle formulation strategy may facilitate antitumor therapy by overcoming the hurdle of low solubility of drugs in order to improve their antitumor efficacy and reduce non-target toxicity. Currently, we are performing additional studies to search for better compositions of micelle formation, and to provide more solid in vivo data to provide evidence to support this strategy. REFERENCES 1. Genevieve. J; Robert, H.M. J Control Release 2010, 143, 2-12. 2. Ho-Chul. S; Adam W. G. Mol Pharmaceutics 2011, 8, 1257–1265. 200 60

Physicochemical Characterization and Biopharmaceutical Evaluation of ZWF: A Novel Anticancer Drug for the Treatment of Non-small Cell Lung Cancer

Preformulation Studies and Enabling Formulation Selection for an Insoluble Compound at Preclinical Stage-from in Vitro, in Silico to in Vivo.

Administration in fed state but not controlled release in the colon increases oral bioavailability of DF030263, a promising drug candidate for chronic lymphocytic leukemia

Pressure-induced amorphous zeolitic imidazole frameworks with reduced toxicity and increased tumor accumulation improves therapeutic efficacy In vivo

Novel Biological Functions of ZIF‐NP As a Delivery Vehicle: High Pulmonary Accumulation, Favorable Biocompatibility, and Improved Therapeutic Outcome

Elucidating the in vivo fate of nanocrystals using a physiologically based pharmacokinetic model: a case study with the anticancer agent SNX-2112

In Vivo Anti-Tumor Efficacy Study of a Novel Wnt pathway Inhibitor Packed in RH 40 Micelles

Preclinical Pharmacodynamic Evaluation of Drug Candidate Sklb-178 in the Treatment of Non-Small Cell Lung Cancer

Abstract 1862: ZW191 - a FRα-targeting antibody drug conjugate with strong preclinical activity across multiple FRα-expressing indications

Abstract 1672: Preclinical Evaluation of WXFL1024H251, a Potent Second-Generation HSP90 Inhibitor

Evaluation of Pluronic Nanosuspensions Loading a Novel Insoluble Anticancer Drug Both in Vitro and in Vivo.

Nanocrystal-loaded liposome for targeted delivery of poorly water-soluble antitumor drugs with high drug loading and stability towards efficient cancer therapy

In vitro and in vivo evaluation of cationic liposomes containing zoledronic acid as anticancer agent

Carfilzomib Delivery by Quinic Acid-Conjugated Nanoparticles: Discrepancy Between Tumoral Drug Accumulation and Anticancer Efficacy in a Murine 4T1 Orthotopic Breast Cancer Model

Chemical Derivatization of the Anticancer Agent Cabazitaxel Using a Polyunsaturated Fatty Acid for Safe Drug Delivery in Vivo.

Zeolitic Imidazolate Framework (ZIF-8) Decorated Iron Oxide Nanoparticles Loaded Doxorubicin Hydrochloride for Osteosarcoma Treatment - in vitro and in vivo Preclinical Studies

OSW-1: A Novel Anticancer Agent with Potent Anticancer Activity and Unique Mechanism of Action.

Physical characterization and bioavailability assessment of 5-fluorouracil-based nanostructured lipid carrier (NLC): In vitro drug release, Hemolysis, and permeability modulation

Oral Delivery of Anti-Mdm2 Inhibitor Sp141-Loaded Fcrn-Targeted Nanoparticles to Treat Breast Cancer and Metastasis

Synthesis and Biological Evaluation of Novel Folic Acid Receptor-Targeted, Β-Cyclodextrin-based Drug Complexes for Cancer Treatment.

Zein nanoparticles as nontoxic delivery system for maytansine in the treatment of non-small cell lung cancer